tradingkey.logo

Breathe BioMedical Ord Shs (Proposed)

BRTH
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
--Market Cap
--P/E TTM

Breathe BioMedical Ord Shs (Proposed)

0.0000.00%

More Details of Breathe BioMedical Ord Shs (Proposed) Company

Breathe BioMedical Inc. is a medical technology company. It is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with specific diseases. It is developing a proprietary end-to-end breath analytics platform, the intended use of which is to enable breath testing for the detection of disease. Its platform technology combines three advanced technologies to sample, digitize and analyze breath with the potential to detect multiple diseases. Its spectrometer technology uses Cavity Ring-Down Spectroscopy (CRDS) to measure the volatile organic compounds (VOCs) in breath samples which are collected using its breath sampler device (SohnoXB). Spectrometer is designed to be very fast, permitting sample analysis down to parts-per-trillion levels.

Breathe BioMedical Ord Shs (Proposed) Info

Ticker SymbolBRTH
Company nameBreathe BioMedical Inc
IPO date- -
CEODawes (William)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address191 Halifax Street
CityMONCTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeE1C 9R7
Phone19024148148
Websitehttps://breathebiomedical.com/
Ticker SymbolBRTH
IPO date- -
CEODawes (William)

Company Executives of Breathe BioMedical Ord Shs (Proposed)

Name
Name/Position
Position
Shareholding
Change
Mr. William Dawes
Mr. William Dawes
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Sandra Veenstra
Ms. Sandra Veenstra
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Ms. Peili Miao
Ms. Peili Miao
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher Purves
Mr. Christopher Purves
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Rachel Brem, M.D.
Dr. Rachel Brem, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Ms. Joanne Young
Ms. Joanne Young
Vice President, Clinical
Vice President, Clinical
--
--
Mr. Jean Nadeau
Mr. Jean Nadeau
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Telfer Hanson
Mr. Telfer Hanson
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Dr. Norman Betts
Dr. Norman Betts
Independent Director
Independent Director
--
--
Mr. Romeo Goguen
Mr. Romeo Goguen
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. William Dawes
Mr. William Dawes
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Sandra Veenstra
Ms. Sandra Veenstra
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Ms. Peili Miao
Ms. Peili Miao
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher Purves
Mr. Christopher Purves
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Rachel Brem, M.D.
Dr. Rachel Brem, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Ms. Joanne Young
Ms. Joanne Young
Vice President, Clinical
Vice President, Clinical
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%

Institutional Shareholding

Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
No Data

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI